Trial
NCT04730349
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bristol-Myers Squibb
Collaborators
Nektar Therapeutics
Condition
Ependymoma
Intervention
Nivolumab
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-24